ProMIS Neurosciences Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
ProMIS announced positive blinded six-month interim safety and biomarker results from its Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer's disease. Key findings: zero cases of ARIA-E across all 136 evaluable participants (including 11% APOE4 homozygotes), 4.4% total ARIA incidence (all mild), directional declines in plasma pTau217 (~15%) and CSF MTBR-tau243 (~13.3%), and no treatment-related serious adverse events. Cash position increased from $6.1M (Dec 2025) to $53.4M (Jun 2026) following a $70.1M private placement in January 2026; company expects to fund operations through 2027, beyond the anticipated Q1 2027 topline readout.
Why this rating
Significant for a $29.7M market-cap company. Lead asset shows strong early safety/biomarker signals; $53.4M cash extends runway well past near-term catalyst. Risks: Phase 1b interim data may not predict Phase 2/3 outcomes; 12-month topline critical for value inflection.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.